EN DE
Watch STAAR Surgical Company for free: we tell you when fair value or trend changes.
Data-driven stock valuation

STAAR Surgical Company (STAA) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of STAAR Surgical Company stock $20.05, price $26.69, that is 24.9% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US8523123052

SS STAAR Surgical Company logo Thin data Nov 10, 2026

STAAR Surgical Company

STAA · US
Expensive, weak quality

Our calculation puts a fair price 25% below what the stock costs today.

Low debt
Positive coverage
Revenue last quarter +111% vs. a year ago.
Quality 44/100
Thin margins · 1.1% net margin (TTM)
Fair value $20.05 · Overvalued
Weak Growth (revenue 3y −5.6 %/yr in USD)
Negative free cash flow
Trails peers (3/13)
Narrow moat 23/100 · thin data
Thin data
Estimate
Watch STAAR Surgical Company for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$162.68 $15.09 Fair Value $20.05 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $15.09 – $162.68 · fair‑value band $15.04 – $25.06 · the $26.69 price screens above the $20.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow STAAR Surgical in your weekly email

Every Wednesday you see whether STAAR Surgical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.

Show moreShow less

The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists.

The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.

STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Stock analysis

STAAR Surgical Company (STAA) currently trades at $26.69, while our estimate is $20.05, 25% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $15.04 (bear) to $25.06 (bull), the price of $26.69 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

STAAR Surgical Company reported revenue of $239M in FY2025 versus $230M in FY2021, a compound +1.0%/yr. Reported net income was −$80.4M in FY2025.

Key figures

Market cap $1.4B Small · P/E ratio 333.6 · P/S ratio 4.05 · EPS (TTM) $0.0800 · Net margin 1.1% · Return on equity 1.1% · Return on assets (EBIT) 2.7% (5-year average) · Operating margin 10.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 20% below its 52-week high and 66% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −25%, STAA screens cheaper than that median.

Fair Value

Bear $15.04 Fair Value $20.05 Bull $25.06
Price $26.69 · Downside -24.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 27
How calm the share price moves, does not count
Price momentum 29
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 46
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyBROADWOOD CAPITAL INC10% owner670,213 shares at $18.31$12.3MMar 13, 2026
  • BuyNeal C Bradsher10% owner3× since Nov 19, 2025: 1,934,138 shares, avg. $26.10$50.5MJan 9, 2026

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−23.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2020 (pandemic). Over 10 years: +12.0% a year
Revenue growth 37 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
4.1% (2020) → −19.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

STAA screens overvalued: fair value 25% below the price. Compare with Intuitive Surgical, Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare STAAR Surgical Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 197 stocks

Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Bottom 25%
Fair Value upside −24.9% · Below median
Profitability
Return on equity (12 months) 1.1% · Below median
Return on assets −17.4% · Bottom 25%
Net margin (12 months) 1.1% · Below median
Operating margin (12 months) 10.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 111.0% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 333.6× · Priciest 25%
P/B 3.99× · Priciest 25%
P/S (12 months) 4.05× · Pricier than median
EV/EBITDA 24.6× · Priciest 25%
PEG 0.76× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)100 · sector 39
PAST (return on equity)4 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $88.62 $131.27 +48% vs STAA
EssilorLuxottica Société anonyme EL €182.55 €196.22 +7% vs STAA
Intuitive Surgical, Inc ISRG $449.53 $353.90 −21% vs STAA
Medline Inc MDLN $42.16 $28.59 −32% vs STAA
Alcon Inc ALC CHF 59.48 CHF 34.29 −42% vs STAA
Becton, Dickinson and Company BDX $214.52 $97.80 −54% vs STAA
Straumann Holding STMN CHF 106.65 CHF 45.50 −57% vs STAA
West Pharmaceutical Services, Inc WST $412.86 $139.22 −66% vs STAA
Sartorius Stedim Biotech S.A DIM €226.80 €54.82 −76% vs STAA
Sartorius Aktiengesellschaft SRT €229.00 €42.50 −81% vs STAA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

STAAR Surgical Company: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "STAAR Surgical Company Fair Value". https://www.fairvalue-calculator.com/stock/STAA

Frequently asked questions

Is STAAR Surgical Company (STAA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $20.05 versus a price of $26.69, about 25% lower (overvalued).
What is the fair value of STAA?
Our estimate for STAAR Surgical Company is $20.05 (as of Nov 10, 2026), built from audited fundamentals. The current price: $26.69.
What is the quality score of STAA?
STAAR Surgical Company has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for STAAR Surgical Company (STAA)?
Our calculated price target is the estimate of $20.05 (as of Nov 10, 2026). Cautious scenario $15.04, optimistic scenario $25.06. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the STAAR Surgical Company stock forecast for 2026?
Our estimate puts fair value at $20.05, about 25% lower versus a price of $26.69 (overvalued). Cautious scenario $15.04, optimistic scenario $25.06. The calculation is refreshed regularly with new filings.
What is the revenue of STAAR Surgical Company (STAA)?
STAAR Surgical Company reported trailing-twelve-month revenue of about $340M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of STAAR Surgical Company (STAA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For STAAR Surgical Company it is $20.05 per share (as of Nov 10, 2026), against a price of $26.69.
Is STAAR Surgical Company stock overvalued or undervalued in 2026?
As of Nov 10, 2026, STAA trades above its calculated fair value: price $26.69, fair value $20.05, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of STAA?
No. The price is what the market pays today ($26.69); the fair value is what the company's own numbers justify ($20.05). For STAAR Surgical Company the two are $6.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is STAAR Surgical Company worth?
The market values STAAR Surgical Company at about $1.4B (market capitalisation, as of Nov 10, 2026). Per share that is $26.69; our models calculate a fair value of $20.05 per share.
What do the bullish and bearish scenarios say about STAA?
Our models span a range for STAAR Surgical Company: cautious scenario $15.04, base $20.05, optimistic $25.06 per share (as of Nov 10, 2026, price $26.69). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of STAA?
STAAR Surgical Company trades at a price-to-earnings ratio of 333.6 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $20.05 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2018 to 2023), reported earnings: 140.8. Other multiples: PEG 0.8, P/B 4.0, P/S 4.0, EV/EBITDA 24.6.
What is the PEG ratio of STAA?
The PEG ratio of STAAR Surgical Company is 0.76 (P/E divided by earnings growth, as of Nov 10, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of STAAR Surgical Company (STAA)?
Balance-sheet figures for STAAR Surgical Company (as of Nov 10, 2026): return on equity 1.1%, debt of 0.00 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is STAA from its 52-week high?
STAAR Surgical Company trades at $26.69, about 20% below its 52-week high of $33.34 and 66% above the low of $16.10 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $20.05 is for.
Which stocks are comparable to STAAR Surgical Company?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is STAAR Surgical Company stock attractive at the current price?
The data as of Nov 10, 2026: price $26.69, calculated fair value $20.05 (−25%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. STAAR Surgical Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of STAAR Surgical Company (STAA)?
The closing price on Nov 11, 2026 was $26.69. Our estimate is $20.05, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with STAAR Surgical Company right now?
The price sits above even our optimistic bull case ($25.06). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of STAAR Surgical Company

How large is the market capitalisation of STAAR Surgical Company (STAA)?
The market capitalisation of STAAR Surgical Company is $1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of STAAR Surgical Company (STAA)?
The price-to-sales ratio of STAAR Surgical Company is 4.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of STAAR Surgical Company (STAA)?
Earnings per share at STAAR Surgical Company are $0.0800 (price ÷ EPS = P/E 333.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of STAAR Surgical Company (STAA)?
The net margin of STAAR Surgical Company is 1.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of STAAR Surgical Company (STAA)?
The return on equity (ROE) of STAAR Surgical Company is 1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of STAAR Surgical Company (STAA)?
On an EBIT basis the return on assets of STAAR Surgical Company is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of STAAR Surgical Company (STAA)?
The operating margin of STAAR Surgical Company is 10.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at STAAR Surgical Company (STAA)?
Revenue at STAAR Surgical Company is growing +111% versus a year earlier (3y avg −5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at STAAR Surgical Company (STAA)?
Earnings per share at STAAR Surgical Company are growing −10.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does STAAR Surgical Company (STAA) generate?
The free cash flow of STAAR Surgical Company is −$40.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does STAAR Surgical Company (STAA) hold?
STAAR Surgical Company holds more cash than debt, $115M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch STAAR Surgical Company in the live analysis

One click puts STAAR Surgical Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.